Sominone

CAS# 98569-64-3

Sominone

Catalog No. BCN8006----Order now to get a substantial discount!

Product Name & Size Price Stock
Sominone:5mg Please Inquire In Stock
Sominone:10mg Please Inquire In Stock
Sominone:20mg Please Inquire In Stock
Sominone:50mg Please Inquire In Stock

Quality Control of Sominone

Number of papers citing our products

Chemical structure

Sominone

3D structure

Chemical Properties of Sominone

Cas No. 98569-64-3 SDF Download SDF
PubChem ID 44249449 Appearance Powder
Formula C28H42O5 M.Wt 458.63
Type of Compound Steroids Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name (2R)-2-[(1S)-1-[(1S,3R,8S,9S,10R,13S,14S,17R)-1,3-dihydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl]-5-(hydroxymethyl)-4-methyl-2,3-dihydropyran-6-one
SMILES CC1=C(C(=O)OC(C1)C(C)C2CCC3C2(CCC4C3CC=C5C4(C(CC(C5)O)O)C)C)CO
Standard InChIKey FYYIHVSEGVWNCF-RMDUJBCISA-N
Standard InChI InChI=1S/C28H42O5/c1-15-11-24(33-26(32)20(15)14-29)16(2)21-7-8-22-19-6-5-17-12-18(30)13-25(31)28(17,4)23(19)9-10-27(21,22)3/h5,16,18-19,21-25,29-31H,6-14H2,1-4H3/t16-,18+,19-,21+,22-,23-,24+,25-,27+,28-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Sominone

The herbs of Physali alkekengi

Biological Activity of Sominone

Description1. Sominone improves memory impairments and increases axonal density in Alzheimer's disease model mice. 2. Sominone enhances neurite outgrowth and spatial memory mediated by the neurotrophic factor receptor, RET.
TargetsBeta Amyloid

Sominone Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Sominone Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Sominone

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.1804 mL 10.902 mL 21.8041 mL 43.6081 mL 54.5102 mL
5 mM 0.4361 mL 2.1804 mL 4.3608 mL 8.7216 mL 10.902 mL
10 mM 0.218 mL 1.0902 mL 2.1804 mL 4.3608 mL 5.451 mL
50 mM 0.0436 mL 0.218 mL 0.4361 mL 0.8722 mL 1.0902 mL
100 mM 0.0218 mL 0.109 mL 0.218 mL 0.4361 mL 0.5451 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Sominone

Sominone improves memory impairments and increases axonal density in Alzheimer's disease model mice, 5XFAD.[Pubmed:21329473]

Int J Neurosci. 2011 Apr;121(4):181-90.

Previously we showed that steroidal sapogenin, Sominone improved memory after a single i.p. injection into normal mice. However, it had not been reported that Sominone could recover memory deficits in a severe Alzheimer's disease (AD) model animal. Therefore, we aimed to investigate that Sominone improved memory impairments in the 5XFAD mouse, model for AD. In the current study, we used Sominone that we had synthesized. 5XFAD mice were given 10 mumol/kg Sominone intraperitoneally for 9 days. In addition to object recognition memory, axonal density, amyloid plaque number, and activated microglia in the brain were evaluated. Sominone treatment significantly improved object recognition memory compared with vehicle control treatment. Sominone treatment significantly enhanced axonal densities in the frontal cortex and parietal cortex but had no effects on amyloid plaque number and activated microglia. In cultured cortical neurons, the axonal length was significantly reduced by Abeta(1-42) treatment. However, that was markedly recovered 5 days after the treatment with 1 muM Sominone. Neuronal loss was not observed in the cortex and hippocampus of 5XFAD mice at 6-8 months of age. These results suggest that memory deficits in AD may be improved by Sominone independently of reducing amyloid plaques and neuroinflammation.

Sominone enhances neurite outgrowth and spatial memory mediated by the neurotrophic factor receptor, RET.[Pubmed:19594760]

Br J Pharmacol. 2009 Aug;157(8):1427-40.

BACKGROUND AND PURPOSE: Orally administered withanoside IV (a compound isolated from the roots of Withania somnifera) improved memory deficits in mice with a model of Alzheimer's disease induced by the amyloid peptide Abeta(25-35). Sominone, an aglycone of withanoside IV, was identified as an active metabolite after oral administration of withanoside IV. We aimed to identify receptors or associated molecules of Sominone, and to investigate the effects of Sominone on memory in normal mice. EXPERIMENTAL APPROACH: Phosphorylation levels of 71 molecules were compared between control and Sominone-stimulated cortical cultured cells to search for target molecules of Sominone. Object location memory and neurite density in the brain were evaluated in Sominone-injected mice. KEY RESULTS: Phosphorylation of RET (a receptor for the glial cell line-derived neurotrophic factor, GDNF) was increased in neurons by Sominone, without affecting the synthesis and secretion of GDNF. Knockdown of RET prevented Sominone-induced outgrowths of axons and dendrites. After a single i.p. injection of Sominone into normal mice, they could better memorize scenery information than control mice. Sixty minutes after Sominone injection, RET phosphorylation was increased, particularly in the hippocampus of mice. After the memory tests, the densities of axons and dendrites were increased in the hippocampus by Sominone administration. CONCLUSIONS AND IMPLICATIONS: Sominone could reinforce the morphological plasticity of neurons by activation of the RET pathway and thus enhance memory. Sominone, a compound with low molecular weight, may be a GDNF-independent stimulator of the RET pathway and/or a novel modulator of RET signalling.

Withanoside IV and its active metabolite, sominone, attenuate Abeta(25-35)-induced neurodegeneration.[Pubmed:16553605]

Eur J Neurosci. 2006 Mar;23(6):1417-26.

At the present, medication of dementia is limited to symptomatic treatments such as the use of cholinesterase inhibitors. To cure dementia completely, that is regaining neuronal function, reconstruction of neuronal networks is necessary. Therefore, we have been exploring antidementia drugs based on reconstructing neuronal networks in the damaged brain and found that withanoside IV (a constituent of Ashwagandha; the root of Withania somnifera) induced neurite outgrowth in cultured rat cortical neurons. Oral administration of withanoside IV (10 micromol/kg/day) significantly improved memory deficits in Abeta(25-35)-injected (25 nmol, i.c.v.) mice and prevented loss of axons, dendrites, and synapses. Sominone, an aglycone of withanoside IV, was identified as the main metabolite after oral administration of withanoside IV. Sominone (1 microM) induced axonal and dendritic regeneration and synaptic reconstruction significantly in cultured rat cortical neurons damaged by 10 microM Abeta(25-35). These data suggest that orally administrated withanoside IV may ameliorate neuronal dysfunction in Alzheimer's disease and that the active principle after metabolism is Sominone.

Keywords:

Sominone,98569-64-3,Natural Products, buy Sominone , Sominone supplier , purchase Sominone , Sominone cost , Sominone manufacturer , order Sominone , high purity Sominone

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: